SCHEMBL4017739

SCHEMBL4017739

Cc1ccc(-c2cc(C(=O)O)c3ccccc3n2)cc1

nearest known ligand 0.80

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 8/20 0.80
KDM4E B2RXH2 4/20 0.79
PDE10A Q9Y233 2/20 0.79
LMNA P02545 2/20 0.79
SMN1; SMN2 Q16637 2/20 0.79
POLB P06746 1/20 0.76
ALDH1A1 P00352 2/20 0.74
HSD17B10 Q99714 1/20 0.74
KMT2A Q03164 1/20 0.69
TP53 P04637 1/20 0.69
MAPT P10636 1/20 0.69
CYP3A4 P08684 1/20 0.67
NPC1 O15118 1/20 0.67
HPGD P15428 1/20 0.67
RAB9A P51151 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29788466 1.00 DHODH (0.80) DHODHKDM4EPDE10ALMNASMN1; SMN2
SCHEMBL29536364 0.89 DHODH (1.00) DHODHKDM4EPDE10ALMNASMN1; SMN2
SCHEMBL2467110 0.89 DHODH (1.00) DHODHKDM4EPDE10ALMNASMN1; SMN2
Cinchophen SCHEMBL25519 0.89 KDM4E (1.00) DHODHKDM4EPDE10ALMNASMN1; SMN2
Cinchophen SCHEMBL7588217 0.89 KDM4E (1.00) DHODHKDM4EPDE10ALMNASMN1; SMN2
Cinchophen SCHEMBL29376617 0.89 KDM4E (1.00) DHODHKDM4EPDE10ALMNASMN1; SMN2
SCHEMBL20414561 0.88 CYP3A4 (0.64) DHODHKDM4EPDE10ALMNASMN1; SMN2
Cinchophen SCHEMBL10757475 0.87 KDM4E (0.97) DHODHKDM4EPDE10ALMNASMN1; SMN2
Cinchophen SCHEMBL4464779 0.87 KDM4E (0.97) DHODHKDM4EPDE10ALMNASMN1; SMN2
Cinchophen SCHEMBL4805149 0.87 KDM4E (0.97) DHODHKDM4EPDE10ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346951-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS YALE UNIVERSITY 2023-11-02 US disclosed
CN-111574530-B ACC inhibitor and medical application thereof 徐州医科大学 2022-07-26 CN disclosed
CN-111574530-A ACC inhibitor and medical application thereof 徐州医科大学 2020-08-25 CN disclosed
WO-2018132905-A1 COMPOUNDS FOR TREATMENT OF GLIOBLASTOMA THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2018-07-26 WO disclosed
WO-2016202898-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-22 WO disclosed
US-20140371165-A1 Identification of NSC23925 Isomers to Reverse Multidrug Resistance in Human Cancers THE GENERAL HOSPITAL CORPORATION (US) 2014-12-18 US disclosed
US-8193225-B2 Isoxazole amides, derivatives and methods of chemical induction of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-06-05 US disclosed
US-7981935-B2 Stem cell differentiating agents and uses therefor THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-07-19 US disclosed
US-20090306133-A1 New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 ASTRAZENECA AB (SE) 2009-12-10 US disclosed
US-20090306133-A1 New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 ASTRAZENECA AB (SE) 2009-12-10 US disclosed
US-7482458-B2 Quinoline derivatives SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) 2009-01-27 US disclosed
US-6828427-B1 Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same ISIS PHARMACEUTICALS, INC. 2004-12-07 US disclosed
US-6750344-B1 MONOCYCLIC AMINE SCAFFOLD BEARING AT LEAST TWO SITES OF DIVERSITY, CYCLIZED TO FORM BICYCLIC AMINE SCAFFOLDS; 7-AMINO-PYRROLO(1,2-A)PYRAZIN-4-ONE COMPOUNDS ISIS PHARMACEUTICALS, INC. 2004-06-15 US disclosed
US-6316626-B1 Amine compounds and combinatorial libraries comprising same ISIS PHARMACEUTICALS, INC. 2001-11-13 US disclosed
EP-0726254-B1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS (JP) 1998-05-06 EP disclosed
US-5627193-A MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION MITSUI TOATSU CHEMICALS, INC. (JP) 1997-05-06 US disclosed
EP-0726254-A1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS, Inc. (JP) 1996-08-14 EP disclosed
US-4711890-A TREATMENT OF ANXIETY STATES OR OF PULMONARY, RENAL, CIRCULATORY OF CARDIOVASCULAR DISORDERS RHONE-POULENC SANTE (FR) 1987-12-08 US disclosed
US-4684652-A TREATING ANXIETY OR CARDIOVASCULAR DISORDERS RHONE-POULENC SANTE (FR) 1987-08-04 US disclosed
US-4433150-A HYPNBOTICS, ANTICONVULSANTS, TRANQUILIZERS, ANTIDEPRESSANTS, SEDATIVES, ANTIARRHYTHMIA AGENTS PHARMINDUSTRIE (FR) 1984-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346951-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS ASGR1, MSR1, LDLR DHODH 4240/4885KDM4E 3430/4885PDE10A 3827/4885
US-20140371165-A1 Identification of NSC23925 Isomers to Reverse Multidrug Resistance in Human Cancers ABCC1, MCL1, ABCB1 DHODH 506/4885KDM4E 3699/4885PDE10A 4337/4885
US-20090306133-A1 New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 ACACA, ACACB, ACAT1 DHODH 1103/4885KDM4E 1761/4885PDE10A 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.